Breaking Barriers: Current Advances and Future Directions in Mpox Therapy.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY Current drug targets Pub Date : 2024-01-01 DOI:10.2174/0113894501281263231218070841

Bhumi M Shah, Palmi Modi

{"title":"Breaking Barriers: Current Advances and Future Directions in Mpox Therapy.","authors":"Bhumi M Shah, Palmi Modi","doi":"10.2174/0113894501281263231218070841","DOIUrl":null,"url":null,"abstract":"Background: Mpox, a newly discovered zoonotic infection, can be transmitted from animal to human and between humans. Serological and genomic studies are used to identify the virus.Objective: Currently, there are no proven effective treatments for Mpox. Also, the safety and efficacy of intravenous vaccinia immune globulin, oral Tecovirimat (an inhibitor of intracellular viral release), and oral Brincidofovir (a DNA polymerase inhibitor) against the Mpox virus are uncertain, highlighting the need for more effective and safe treatments. As a result, drug repurposing has emerged as a promising strategy to identify previously licensed drugs that can be repurposed to treat Mpox.Results: Various approaches have been employed to identify previously approved drugs that can target specific Mpox virus proteins, including thymidylate kinase, D9 decapping enzyme, E8 protein, Topoisomerase1, p37, envelope proteins (D13, A26, and H3), F13 protein, virus's main cysteine proteases, and DNA polymerase.Conclusion: In this summary, we provide an overview of potential drugs that could be used to treat Mpox and discuss the underlying biological processes of their actions.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"62-76"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501281263231218070841","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Mpox, a newly discovered zoonotic infection, can be transmitted from animal to human and between humans. Serological and genomic studies are used to identify the virus.

Objective: Currently, there are no proven effective treatments for Mpox. Also, the safety and efficacy of intravenous vaccinia immune globulin, oral Tecovirimat (an inhibitor of intracellular viral release), and oral Brincidofovir (a DNA polymerase inhibitor) against the Mpox virus are uncertain, highlighting the need for more effective and safe treatments. As a result, drug repurposing has emerged as a promising strategy to identify previously licensed drugs that can be repurposed to treat Mpox.

Results: Various approaches have been employed to identify previously approved drugs that can target specific Mpox virus proteins, including thymidylate kinase, D9 decapping enzyme, E8 protein, Topoisomerase1, p37, envelope proteins (D13, A26, and H3), F13 protein, virus's main cysteine proteases, and DNA polymerase.

Conclusion: In this summary, we provide an overview of potential drugs that could be used to treat Mpox and discuss the underlying biological processes of their actions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

打破障碍：麻疹治疗的当前进展和未来方向。

背景：麻疹病毒是一种新发现的人畜共患传染病，可在动物之间和人与人之间传播。血清学和基因组研究被用来识别这种病毒：目的：目前还没有被证实有效的治疗麻风腮病毒的方法。此外，静脉注射疫苗免疫球蛋白、口服 Tecovirimat（一种细胞内病毒释放抑制剂）和口服 Brincidofovir（一种 DNA 聚合酶抑制剂）对麻风腮病毒的安全性和有效性也不确定，因此需要更有效、更安全的治疗方法。因此，药物再利用已成为一种很有前景的策略，它可以找出以前获得许可的药物，并将其重新用于治疗痘病毒：结果：我们采用了多种方法来确定以前批准的可针对特定 Mpox 病毒蛋白的药物，包括胸苷酸激酶、D9 解旋酶、E8 蛋白、拓扑异构酶 1、p37、包膜蛋白（D13、A26 和 H3）、F13 蛋白、病毒的主要半胱氨酸蛋白酶和 DNA 聚合酶：在本摘要中，我们概述了可用于治疗麻风腮的潜在药物，并讨论了这些药物作用的基本生物学过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.